Skip to main content

Table 2 Comparison between the preinjection and the postinjection assessments regarding outcomes measures and procedure assessment

From: Efficacy of neural prolotherapy in treatment of meralgia paresthetica: a case series

Outcomes measures Preinjection assessment
(n = 19 lower limbs from 15 patients)§
Postinjection assessment
(n = 19 lower limbs from 15 patients)§
Test of significance|| P
Overall MP symptoms (VAS)† 7(7.00 ± 1.49) 1(1.84 ± 1.80) -3.848 ≤ 0.0001*
MP pain (VAS)† 6(6.42 ± 1.92) 1(1.94 ± 1.87) -3.745  ≤ 0.0001*
MP paresthesia (VAS)† 7(7.31 ± 1.49) 1(1.89 ± 2.13) -3.835  ≤ 0.0001*
MP effect on function and QoL (VAS)† 5(5.57 ± 1.67) 0(1.05 ± 1.47) -3.839  ≤ 0.0001*
Procedure assessment
Immediately postinjection MP pain (VAS)† 0(0) NA NA NA
Injection procedure-induced pain (VAS)† 2.5(2.44 ± 0.81) NA NA NA
Presence of injection procedure side effects‡ NA 1(5.3) NA NA
Degree of satisfaction regarding the procedure (VAS)† NA 8(7.42 ± 2.75) NA NA
  1. MP meralgia paresthetica; VAS visual analogue scale; overall MP symptoms; patient assessment of overall MP symptoms; MP pain; patient assessment of MP pain; MP paresthesia; patient assessment of MP paresthesia; QoL quality of life; MP effect on function and QoL; patient assessment of MP effect on function and QoL; n number of lower limbs; NA not applicable
  2. *P is significant at < 0.05
  3. Data are reported as median (mean ± standard deviation)
  4. Data are reported as number (percentage) of lower limbs
  5. §There were four patients with bilateral meralgia paresthetica
  6. ||Value of Wilcoxon Signed Ranks test